Fig. 7: NK cells slow down growth and recurrence of MYC-driven lymphomas.
a Bioluminescence imaging (BLI) of NOD-SCID (n = 10) and NOD-SCIDIL2Rγ−/− (NSG, n = 10) mice transplanted with SRα-tTA MYCON mouse T-lymphoma cells post injection to monitor lymphoma engraftment and initiation. b Comparison of survival probabilities of NOD-SCID (n = 10) and NOD-SCIDIL2Rγ−/− (NSG, n = 10) T-lymphoma transplant recipients. c BLI of NSG T cell lymphoma transplant recipients comparing lymphoma engraftment and initiation in the presence (n = 9) and absence (n = 9) of NK cells syngeneic to the tumor. d Quantification of changes in BLI signal of NSG transplant recipients that received vehicle or syngeneic NK cells before transplantation of T-lymphoma cells. e BLI of NSG T cell lymphoma transplant recipients comparing recurrence rates upon MYC inactivation in the absence (MYCOFF + vehicle, n = 8) or presence of NK cells (MYCOFF + Adoptive NK transfer, n = 8). f Quantification of changes in BLI signal (left) and absolute signals (middle and right) at the time of lymphoma regression (d7 MYCOFF) and lymphoma relapse (d21 MYCOFF). g Comparison of survival probabilities of NSG T-lymphoma transplant recipients that received either vehicle (n = 8) or adoptive NK transfer (n = 8) at the time of MYC inactivation (MYCOFF). p-values for all survival analyses have been calculated using the log-rank test. p-values for all other analyses have been calculated using a two-tailed Mann–Whitney test. ns not significant. For all box plots, the center is at the median, minima and maxima are indicated by whiskers, and the box represents data between the 25th and 75th percentile.
